THE IMPACT OF POLYCYSTIC OVARY SYNDROME ON REPRODUCTIVE HEALTH AND MODERN TREATMENT APPROACHES

Authors

  • Xudayberdiyeva Ruqiya Jamoliddin qizi Samarkand State Medical University, Samarkand, Uzbekistan Author
  • Sayfullayeva Hilola Xasan qizi Samarkand State Medical University, Samarkand, Uzbekistan Author
  • Axtamova Nilufar Akbarjanovna Samarkand State Medical University, Samarkand, Uzbekistan Author

Keywords:

polycystic Ovary Syndrome (PCOS), reproductive health, anovulatory infertility, insulin resistance, hyperandrogenism, Letrozole, Clomiphene Citrate, myo-inositol, ovulation induction.

Abstract

Polycystic Ovary Syndrome (PCOS) is the most prevalent endocrine-metabolic disorder among women of reproductive age and the leading cause of anovulatory infertility worldwide. Its complex pathophysiology, driven by hyperandrogenism and insulin resistance, severely compromises reproductive function, leading to chronic anovulation, poor oocyte quality, and elevated miscarriage rates.

References

1.Bozdag, G., Mumusoglu, S., Zengin, D., Karabulut, E., & Yildiz, B. O. (2016). The prevalence and phenotypic features of polycystic ovary syndrome: A systematic review and meta-analysis. Human Reproduction, 31(12), 2841-2855.

2.Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction, 19(1), 41-47.

3.McCartney, C. R., & Marshall, J. C. (2016). Clinical practice: Polycystic ovary syndrome. The New England Journal of Medicine, 375(1), 54-64.

4.Diamanti-Kandarakis, E., & Dunaif, A. (2019). Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications. Endocrine Reviews, 33(6), 981-1030.

5.Rosenfield, R. L., & Ehrmann, D. A. (2016). The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocrine Reviews, 37(5), 467-520.

6.Norman, R. J., Dewailly, D., Legro, R. S., & Hickey, T. E. (2021). Polycystic ovary syndrome. The Lancet, 370(9588), 685-697.

7.Palomba, S., de Wilde, M. A., Falbo, A., Koster, M. P. H., La Sala, G. B., & Fauser, B. C. J. M. (2015). Pregnancy complications in women with polycystic ovary syndrome. Human Reproduction Update, 21(5), 575-592.

8.Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., ... & Yildiz, B. O. (2023). Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction, 33(9), 1602-1618.

9.Legro, R. S., Brzyski, R. G., Diamond, M. P., Coutifaris, C., Schlaff, W. D., Casson, P., ... & NICHD Reproductive Medicine Network. (2014). Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. The New England Journal of Medicine, 371(2), 119-129.

10.Franik, S., Eltrop, S. M., Kremer, J. A., Kiesel, L., & Farquhar, C. (2018). Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews, (5), CD010287.

11.Facchinetti, F., Appetecchia, M., Aragona, C., Bevilacqua, A., Bezerra Espinola, M. S., Bizzarri, M., ... & D'Anna, R. (2015). Experts' opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: A further help for human reproduction and beyond. Expert Opinion on Drug Metabolism & Toxicology, 11(10), 1653-1669.

Downloads

Published

2026-05-26